Publications by authors named "Ye-Hong Xu"
Article Synopsis
- Bone or brain metastases occur in 20-40% of late-stage non-small-cell lung cancer (NSCLC) patients, leading to a poor median survival of 4-6 months, yet the distinctions in metastatic types at the single-cell level remain underexplored.
- A comprehensive analysis of 14 biopsy samples from treatment-naïve advanced NSCLC patients revealed significant differences in cancer-associated fibroblast (CAF) populations among the bone, brain, and intrapulmonary metastases.
- The study highlights the role of specific CAF subpopulations in promoting either bone or brain metastasis and suggests potential therapeutic targets by disrupting their interactions with tumor cells to inhibit metastasis.
Background: A paucity of strategies exist for extensive-stage small cell lung cancer (ES-SCLC) patients who fail the first-line chemotherapy. Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), which has been demonstrated to have active anti-tumor activity in ES-SCLC when used only or combined with PD-1 inhibitors or chemotherapy with good tolerance. However, the efficacy and safety of apatinib monotherapy is unclear in second-line or beyond treatment of ES-SCLC.
View Article and Find Full Text PDF